Vertex Pharmaceuticals Incorporated

BATS-CHIXE:VX1D Stock Report

Market Cap: €116.5b

Vertex Pharmaceuticals Past Earnings Performance

Past criteria checks 6/6

Vertex Pharmaceuticals has been growing earnings at an average annual rate of 15.1%, while the Biotechs industry saw earnings growing at 10.9% annually. Revenues have been growing at an average rate of 20.6% per year. Vertex Pharmaceuticals's return on equity is 21.7%, and it has net margins of 39.5%.

Key information

15.1%

Earnings growth rate

15.1%

EPS growth rate

Biotechs Industry Growth11.5%
Revenue growth rate20.6%
Return on equity21.7%
Net Margin39.5%
Next Earnings Update01 Aug 2024

Recent past performance updates

Recent updates

Revenue & Expenses Breakdown

How Vertex Pharmaceuticals makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

BATS-CHIXE:VX1D Revenue, expenses and earnings (USD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
31 Mar 2410,1854,0191,2380
31 Dec 239,8693,6201,1370
30 Sep 239,6543,4701,0350
30 Jun 239,5053,3651,0180
31 Mar 239,2083,2609710
31 Dec 228,9313,3229450
30 Sep 228,7013,2739330
30 Jun 228,3503,1958840
31 Mar 227,9482,4518630
31 Dec 217,5742,3428400
30 Sep 217,1302,1767970
30 Jun 216,6841,9927830
31 Mar 216,4152,7627800
31 Dec 206,2062,7127710
30 Sep 205,9912,6917540
30 Jun 205,4032,0817290
31 Mar 204,8191,5116940
31 Dec 194,1631,1776590
30 Sep 193,6202,1446160
30 Jun 193,4542,2155940
31 Mar 193,2652,1555750
31 Dec 183,0482,0965580
30 Sep 182,8296475390
30 Jun 182,6234155230
31 Mar 182,4152265130
31 Dec 172,4892634960
30 Sep 172,2961964710
30 Jun 172,1312594570
31 Mar 172,0191774410
31 Dec 161,702-1124330
30 Sep 161,661-2194190
30 Jun 161,557-2754130
31 Mar 161,292-3993960
31 Dec 151,032-5563770
30 Sep 15759-6593590
30 Jun 15628-7343340
31 Mar 15600-7043170
31 Dec 14580-7383050
30 Sep 14787-5823000
30 Jun 14830-5303080
31 Mar 141,002-4283380
31 Dec 131,212-5043560
30 Sep 131,195-5593940

Quality Earnings: VX1D has high quality earnings.

Growing Profit Margin: VX1D's current net profit margins (39.5%) are higher than last year (35.4%).

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: VX1D's earnings have grown by 15.1% per year over the past 5 years.

Accelerating Growth: VX1D's earnings growth over the past year (23.3%) exceeds its 5-year average (15.1% per year).

Earnings vs Industry: VX1D earnings growth over the past year (23.3%) exceeded the Biotechs industry 2.8%.

Return on Equity

High ROE: VX1D's Return on Equity (21.7%) is considered high.

Return on Assets

Return on Capital Employed

Discover strong past performing companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/07/22 04:20
End of Day Share Price 2024/04/24 00:00
Earnings2024/03/31
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Vertex Pharmaceuticals Incorporated is covered by 77 analysts. 31 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Jasper HellwegArgus Research Company
Brian SkorneyBaird
Ishan MajumdarBaptista Research